131,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Gebundenes Buch

Pharmaceutical Economics and Policy provides comprehensive discussions on a wide range of pharmaceutical economics and policy issues. This third edition re-examines ongoing issues such as industrial organization, R&D and innovation, competition and pricing, intellectual property and regulation. It includes a number of new topics, such as the nascent biosimilar sector, globalization of supply chain, value-based pricing, evolving reimbursement landscape,and the emerging pharmaceutical market in large, developing economies such as China and India.

Produktbeschreibung
Pharmaceutical Economics and Policy provides comprehensive discussions on a wide range of pharmaceutical economics and policy issues. This third edition re-examines ongoing issues such as industrial organization, R&D and innovation, competition and pricing, intellectual property and regulation. It includes a number of new topics, such as the nascent biosimilar sector, globalization of supply chain, value-based pricing, evolving reimbursement landscape,and the emerging pharmaceutical market in large, developing economies such as China and India.
Autorenporträt
Stuart O. Schweitzer is Professor of Health Policy and Management at UCLA's Fielding School of Public Health. He has held other academic and research appointments at the Urban Institute and the White House Commission for a National Agenda for the Eighties. His research and consulting activities have dealt with pharmaceutical regulation and policy, health care financing, and technology assessment. Z. John Lu is an Assistant Professor of Economics at the MVS School of Business and Economics, California State University, Channel Islands. Prior to this academic position, Dr. Lu was a health economist in the biopharmaceutical industry for 2 decades, including nearly 17 years at Amgen, where he was a director of global health economics and policy. Professor Lu's research interests include industrial economics and policy on pharmaceuticals, particularly in the United States and China.